{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:10:14Z","timestamp":1783552214563,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We describe the management trends of patients suffering from any priapism and evaluate the risks of developing priapism after intracavernosal injections (ICI) performed in office. We queried TriNetX for two separate male adult cohorts - those presenting with any priapism based on International Classification of Disease code, N48.3 (priapism) and those who underwent ICI in office based on Current Procedural Terminology code, 54235 (injection of corpora cavernosa with pharmacologic agent[s]). We evaluated treatment options for these patients after any priapism and described demographic risks for developing priapism after ICI performed in office. There were 17,545 priapism encounters and 26,104 usages of ICI in the office. Most common treatment for any priapism was corporal irrigation\/injection of medications (11.3%). Patients presenting with priapism after ICI were younger (age\u2009&gt;\u200965 years, OR 0.44 [95% CI 0.38\u20130.51],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and had a higher prevalence of mood disorders (20% vs 14%), behavioral disorders (7% vs 2%) and sickle cell disease (6% vs &lt;1%). They were less likely to have diabetes (14% vs 22%), hypertension (33% vs 40%), prostate cancer (13% vs 25%) or have taken sildenafil or tadalafil (29\u201330% vs 35\u201338%). For patients administering ICI, proper screening and counseling of priapism is important to reduce complications.\n                  <\/jats:p>","DOI":"10.1038\/s41443-024-00861-2","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:02:49Z","timestamp":1709730169000},"page":"465-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the management trends for priapism and assessing the risk of priapism after in-office intracavernosal injections: a cross-sectional analysis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1698-8442","authenticated-orcid":false,"given":"Joon Yau","family":"Leong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9494-9633","authenticated-orcid":false,"given":"Zachary J.","family":"Prebay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ebbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2637","authenticated-orcid":false,"given":"Michael","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-1400","authenticated-orcid":false,"given":"Paul H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"861_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1080\/14656566.2022.2099271","volume":"23","author":"BA Graham","year":"2022","unstructured":"Graham BA, Wael A, Jack C, Rohan MA, Wayne HJG. An overview of emergency pharmacotherapy for priapism. Expert Opin Pharmacother. 2022;23:1371\u201380.","journal-title":"Expert Opin Pharmacother"},{"key":"861_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41443-022-00583-3","volume":"36","author":"N Schifano","year":"2024","unstructured":"Schifano N, Capogrosso P, Boeri L, Fallara G, Cakir OO, Castiglione F, et al. Medications mostly associated with priapism events: assessment of the 2015\u20132020 Food and Drug Administration (FDA) pharmacovigilance database entries. Int J Impot Res. 2024;36:50\u20134.","journal-title":"Int J Impot Res"},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41443-022-00590-4","volume":"36","author":"M G\u00fcl","year":"2024","unstructured":"G\u00fcl M, Luca B, Dimitropoulos K, Capogrosso P, Milenkovic U, Cocci A, et al. What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. Int J Impot Res. 2024;36:20\u201335.","journal-title":"Int J Impot Res"},{"key":"861_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41443-022-00604-1","volume":"36","author":"U Milenkovic","year":"2024","unstructured":"Milenkovic U, Cocci A, Veeratterapillay R, Dimitropoulos K, Boeri L, Capogrosso P, et al. Surgical and minimally invasive treatment of ischaemic and non-ischaemic priapism: a systematic review by the EAU Sexual and Reproductive Health Guidelines panel. Int J Impot Res. 2024;36:36\u201349.","journal-title":"Int J Impot Res"},{"key":"861_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41443-022-00592-2","volume":"36","author":"P Capogrosso","year":"2024","unstructured":"Capogrosso P, Dimitropolous K, Russo GI, Tharakan T, Milenkovic U, Cocci A, et al. Conservative and medical treatments of non-sickle cell disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel. Int J Impot Res. 2024;36:6\u201319.","journal-title":"Int J Impot Res"},{"key":"861_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1439-0272.2009.00940.x","volume":"42","author":"M Kilic","year":"2010","unstructured":"Kilic M, Serefoglu EC, Ozdemir AT, Balbay MD. The actual incidence of papaverine-induced priapism in patients with erectile dysfunction following penile colour Doppler ultrasonography. Andrologia. 2010;42:1\u20134.","journal-title":"Andrologia."},{"key":"861_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jsxmed\/qdad144","volume":"21","author":"TP Furtado","year":"2023","unstructured":"Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, et al. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. J Sex Med. 2023;21:29\u201332.","journal-title":"J Sex Med"},{"key":"861_CR8","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.esxm.2016.08.001","volume":"5","author":"HL Bernie","year":"2017","unstructured":"Bernie HL, Segal R, Le B, Burnett A, Bivalacqua TJ. An empirical vs risk-based approach algorithm to intracavernosal injection therapy: a prospective study. Sex Med. 2017;5:e31\u20136.","journal-title":"Sex Med"},{"key":"861_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/JU.0000000000002236","volume":"206","author":"TJ Bivalacqua","year":"2021","unstructured":"Bivalacqua TJ, Allen BK, Brock G, Broderick GA, Kohler TS, Mulhall JP, et al. Acute ischemic priapism: an AUA\/SMSNA guideline. J Urol. 2021;206:1114\u201321.","journal-title":"J Urol"},{"key":"861_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41443-019-0120-4","volume":"31","author":"M Butaney","year":"2019","unstructured":"Butaney M, Thirumavalavan N, Rodriguez D, Gross MS, Munarriz R. Current practice in the management of ischemic priapism: an anonymous survey of ISSM members. Int J Impot Res. 2019;31:404\u20139.","journal-title":"Int J Impot Res"},{"key":"861_CR11","unstructured":"International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): Centers for Disease Control and Prevention; 2023. [updated June 29, 2023]. https:\/\/www.cdc.gov\/nchs\/icd\/icd-10-cm.htm."},{"key":"861_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4081\/aiua.2022.2.237","volume":"94","author":"M Moussa","year":"2022","unstructured":"Moussa M, Abou Chakra M, Papatsoris A, Dellis A, Peyromaure M, Barry Delongchamps N, et al. An update on the management algorithms of priapism during the last decade. Arch Ital Urol Androl. 2022;94:237\u201347.","journal-title":"Arch Ital Urol Androl"},{"key":"861_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2021.03.030","volume":"154","author":"J Palka","year":"2021","unstructured":"Palka J, DuComb W, Begun E, Soto-Aviles O. Factors associated with corporoglandular shunting for patients with first-time ischemic priapism. Urology. 2021;154:191\u20135.","journal-title":"Urology."},{"key":"861_CR14","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.jsxm.2020.09.007","volume":"17","author":"H Zhao","year":"2020","unstructured":"Zhao H, Dallas K, Masterson J, Lo E, Houman J, Berdahl C, et al. Risk factors for surgical shunting in a large cohort with ischemic priapism. J Sex Med. 2020;17:2472\u20137.","journal-title":"J Sex Med"},{"key":"861_CR15","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jsxm.2019.07.024","volume":"16","author":"H Zhao","year":"2019","unstructured":"Zhao H, Berdahl C, Bresee C, Moradzadeh A, Houman J, Kim H, et al. Priapism from recreational intracavernosal injections in a high-risk metropolitan community. J Sex Med. 2019;16:1650\u20134.","journal-title":"J Sex Med"},{"key":"861_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/13645706.2011.636821","volume":"21","author":"E Mains","year":"2012","unstructured":"Mains E, Aboumarzouk O, Ahmad S, El-Mokadem I, Nabi G. A minimally invasive temporary cavernoso-saphenous shunt in the management of priapism after failed conservative treatment. Minim Invasive Ther Allied Technol. 2012;21:366\u20138.","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"861_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5534\/wjmh.17040","volume":"36","author":"AG Reddy","year":"2018","unstructured":"Reddy AG, Alzweri LM, Gabrielson AT, Leinwand G, Hellstrom WJG. Role of penile prosthesis in priapism: a review. World J Mens Health. 2018;36:4\u201314.","journal-title":"World J Mens Health"},{"key":"861_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jsm.12803","volume":"12","author":"TJ Tausch","year":"2015","unstructured":"Tausch TJ, Zhao LC, Morey AF, Siegel JA, Belsante MJ, Seideman CA, et al. Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism. J Sex Med. 2015;12:824\u20136.","journal-title":"J Sex Med"},{"key":"861_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bju.12686","volume":"114","author":"E Zacharakis","year":"2014","unstructured":"Zacharakis E, Garaffa G, Raheem AA, Christopher AN, Muneer A, Ralph DJ. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation. BJU Int. 2014;114:576\u201381.","journal-title":"BJU Int"},{"key":"861_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ijir.2011.23","volume":"23","author":"O Sedigh","year":"2011","unstructured":"Sedigh O, Rolle L, Negro CL, Ceruti C, Timpano M, Galletto E, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011;23:158\u201364.","journal-title":"Int J Impot Res"},{"key":"861_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.sxmr.2017.08.002","volume":"6","author":"\u00d6B Y\u00fccel","year":"2018","unstructured":"Y\u00fccel \u00d6B, Paz\u0131r Y, Kad\u0131o\u011flu A. Penile prosthesis implantation in priapism. Sex Med Rev. 2018;6:310\u20138.","journal-title":"Sex Med Rev"},{"key":"861_CR22","doi-asserted-by":"publisher","first-page":"S797","DOI":"10.21037\/tau.2017.04.26","volume":"6","author":"J Moore","year":"2017","unstructured":"Moore J, Whelan TF, Langille GM. The use of penile prostheses in the management of priapism. Transl Androl Urol. 2017;6:S797\u2013803.","journal-title":"Transl Androl Urol"},{"key":"861_CR23","first-page":"512","volume":"17","author":"Y G\u00fcler","year":"2020","unstructured":"G\u00fcler Y, Erbin A. Independent predictive factors for occurrence of ischemic priapism after papaverine injection. Urol J. 2020;17:512\u20136.","journal-title":"Urol J."},{"key":"861_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/0974-7796.165717","volume":"8","author":"DK Pal","year":"2016","unstructured":"Pal DK, Biswal DK, Ghosh B. Outcome and erectile function following treatment of priapism: an institutional experience. Urol Ann. 2016;8:46\u201350.","journal-title":"Urol Ann"},{"key":"861_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.amjsurg.2010.03.017","volume":"201","author":"KL Chrouser","year":"2011","unstructured":"Chrouser KL, Ajiboye OB, Oyetunji TA, Chang DC. Priapism in the United States: the changing role of sickle cell disease. Am J Surg. 2011;201:468\u201374.","journal-title":"Am J Surg"},{"key":"861_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2022000380","volume":"2022","author":"IM Idris","year":"2022","unstructured":"Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematol Am Soc Hematol Educ Program. 2022;2022:450\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00861-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:04:14Z","timestamp":1750698254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-024-00861-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1038\/s41443-024-00861-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3260637\/v1","asserted-by":"object"}]},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}